The diagnostic significance of circulating lncRNA ADAMTS9-AS2 tumor biomarker in non-small cell lung cancer among the Egyptian population

Faculty Medicine Year: 2021
Type of Publication: ZU Hosted Pages:
Authors:
Journal: J Gene Medicine wiley Volume:
Keywords : , diagnostic significance , circulating lncRNA ADAMTS9-AS2 tumor biomarker    
Abstract:
Background: Long non-coding RNA ADAM metallopeptidase with thrombospondin type 1 motif, 9 antisense RNA 2 (ADAMTS9-AS2) was recognized as a novel tumor suppressor and plays an important role in the initiation and progression of malignant behavior in human cancers, although its plasma expression and clinical value in patients with non-small cell lung cancer (NSCLC) remain unknown. We aimed to analyze the diagnostic role of ADAMTS9-AS2 and cytokeratin 19 fragmentation antigen (CYFRA 21-1) in NSCLC. Methods: The present study included 80 control subjects, 80 patients with benign lung lesion and 80 NSCLC patients. The expression of ADAMTS9-AS2 in the tissue and plasma was detected by a real-time polymerase chain reaction. Serum CYFRA 21-1 was analyzed using an enzyme-linked immunosorbent assay. Results: In comparison with benign lung lesion and controls, tissue and plasma ADAMTS9-AS2 expression were significantly down-regulated in NSCLC (p < 0.001). Decreased ADAMTS9-AS2 expression was associated with TNM stages in NSCLC patients (p < 0.001). Up-regulation of CYFRA 21-1 was reported among NSCLC patients and it was associated with TNM staging. Tissue and plasma ADAMTS9-AS2 expression levels were the predicting factors for NSCLC and they both correlated negatively with CYFRA 21-1 levels. Plasma ADAMTS9-AS2 levels had a significant positive correlation with their tumor tissue levels. Plasma ADAMTS9-AS2 showed a higher sensitivity (95%) and specificity (99.1%) in the diagnosis of NSCLC than CYFRA 21-1 (61.3% sensitivity and 60% specificity). Conclusions: Our results suggested that decreased plasma ADAMTS9-AS2 expression might act as a novel non-invasive tumor biomarker in NSCLC diagnosis. Furthermore, plasma ADAMTS9-AS2 might predict aggressive tumor behavior.
   
     
 
       

Author Related Publications

  • Nearmeen Mohammed Rashad Ahmmad, "Circulating miR-181a and miR-223 expression with the potential value of biomarkers for the diagnosis of systemic lupus erythematosus and predicting lupus nephritis", wiley, 2021 More
  • Nearmeen Mohammed Rashad Ahmmad, "Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus", springer, 2021 More
  • Nearmeen Mohammed Rashad Ahmmad, "nterferon-gamma Expression Profile as Diagnostic Signatures of Unexplained Infertility in Female Patients Suffer from Hashimoto's Thyroiditis", Tehran University of Medical Sciences, 2021 More
  • Nearmeen Mohammed Rashad Ahmmad, "Association of miRNA − 320 expression level and its target gene endothelin-1 with the susceptibility and clinical features of polycystic ovary syndrome", BMC, 2019 More
  • Nearmeen Mohammed Rashad Ahmmad, "ntercellular adhesion molecule-1 expression and serum levels as markers of pre-clinical atherosclerosis in polycystic ovary syndrome", BMC, 2019 More

Department Related Publications

  • Khaled Abdelnaby Khodary Mohamed Elhefnawy, "Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) As a Marker for Lupus Nephritis Activity", International Journal of Science and Research (IJSR) Volume 4 Issue 2,, 2015 More
  • Abdallah Abdelaziz Abdullh, "Thyroid Dysfunction In Acute Ischemic Stroke In Medical Intensive Care Unit In zagazig University Hospital", International Journal Of Advanced Resear, 2014 More
  • Abdallah Abdelaziz Abdullh, "Prohepcidin Level Is Decreased In Patients With Viral C Hepatitis And Has No Correlation With Disease Progression", Journal Of American Science, 2012 More
  • Munkez Mutee Yusuf Muhamed, "دراسة المقاومة لعامل بروتين سى المنشط كعامل خطر لحدوث التجلط فى حالات جلطة الشريان التاجى والمخى", لايوجد, 1900 More
  • Khaled Abdelnaby Khodary Mohamed Elhefnawy, "دور الانترلوكين 19 في الاعتلال الكلوي السكري The role of interleukin-19 in diabetic nephropathy", Wolters Kluwer - Medknow, 2020 More
Tweet